Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that future sales of the most promising investigational drugs for treating epilepsy -- UCB's brivaracetam and Schwarz Pharma's lacosamide -- will provide moderate market growth but will be heavily tempered by the sustained commercial success of traditional antiepileptic drugs.

According to the new Pharmacor report entitled Epilepsy, both of these agents are expected to enter the marketplace by 2009, but forecasted peak year sales in excess of $500 million for brivaracetam and $100 million for lacosamide will likely not occur until after 2014. The report also finds that the main driver of growth in this market will be increases in the overall size of the prevalent population, which will account for approximately half of the increase in drug sales.

"People with epilepsy often use the same antiepileptic drugs for decades, and physicians almost never prescribe a generic treatment to replace a branded antiepileptic drug," said Julie A. Kerner, Ph.D., analyst at Decision Resources, Inc. "This practice stems primarily from physicians' fear that a generic will not have the same bioequivalence as a branded drug and that patients may have seizures if their treatment is switched. For this reason, antiepileptic drugs enjoy commercial success long after their patent expires and the launch of competing drugs."

About Epilepsy

Epilepsy is the most common neurological disorder worldwide and the second most common neurological disease in the developed world. Epilepsy encompasses a diverse collection of chronic syndromes that involve the recurrence of many different types of seizures.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-

Humana's Bold Move to Dominate the Managed Medicare Market

View Now